74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Blueprint Medicines Corp
Closed
SectorHealthcare
85.8 0.05
Overview
Share price change
24h
Min
84.19
Max
86.49
Income | 6.3M -50M |
|---|---|
Sales | 18M 146M |
EPS | -0.79 |
Profit margin | -34.131 |
Employees | 649 |
EBITDA | 6.3M -27M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +51.3% upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | 5.4B |
|---|---|
Previous open | 85.75 |
Previous close | 85.8 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Blueprint Medicines Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Blueprint Medicines Corp Forecast
Price Target
By TipRanks
51.3% upside
12 Months Forecast
Average 130.25 USD 51.3%
High 155 USD
Low 100 USD
Based on 18 Wall Street analysts offering 12 month price targets forBlueprint Medicines Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
